Abstracts Archive - Page 172 of 2607 - ACR Meeting Abstracts

Abstract Number: 1094 • ACR Convergence 2025
Changes in NK cells and TH cell phenotype in Rheumatoid Arthritis patients treated with janus kinase inhibitors: implications for adverse effects
Carmen Lasa Teja¹, Juan José Fernández-Cabero², Alejandra Comins-Boo³, David San Segundo³, Virginia Portilla González⁴, Montserrat Santos-Gomez⁵, José Luis Martín-Varillas⁶, Marcos López-Hoyos³ and Ricardo Blanco⁷, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ²Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Cantabria, Spain, ³Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, ⁵Division of Immunology, Hospital Sierrallana. Santander , Spain, Santander, Spain, ⁶Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, ⁷Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Janus kinase inhibitors (JAKi) are effective in rheumatoid arthritis (RA); however, concerns regarding safety, particularly the risk of infections and malignancies, have been raised.…
Abstract Number: 1106 • ACR Convergence 2025
Faster Ellipsoid Zone Loss in Hydroxychloroquine Retinopathy with Tapering versus Discontinuation: A Longitudinal Optical Coherence Tomography Study from a Single Center in Taiwan
Ko-Jen Li¹, Ting-Wei Chang², Tso-Ting Lai³, Jui-Hung Kao⁴, TING-YUAN LAN⁵, Tai-Ju Lee⁶, pei-Hsinq lai⁷, Shao-Yu Pai⁸, Chiehyu Shen⁹ and Song-Chou Hsieh¹⁰, ¹National Taiwan University Hospital, Taipei, Taiwan, ²National Taiwan University Hospital Hsinchu Branch, Taichung, Taiwan, ³Naitional Taiwan University Hospital, Taipei, Taiwan (Republic of China), ⁴Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, Taipei, Taiwan (Republic of China), ⁵National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ⁶National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan (Republic of China), ⁷Taipei City Hospital, Taichung, Taiwan, ⁸National Taiwan University Hospital, Taichung City, Taiwan (Republic of China), ⁹National Taiwan University Hospital, Taipei city, Taiwan, ¹⁰National Taiwan Unuversity Hospital, Taipei City, Taiwan (Republic of China)
Background/Purpose: Hydroxychloroquine (HCQ) retinopathy is a progressive, vision-threatening retinal disease. While HCQ is typically discontinued after toxicity is detected, some patients undergo tapering due to…
Abstract Number: 1122 • ACR Convergence 2025
A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-Related Problems
William Koch¹, Donald Anthony², Janeen Leon² and Nora G. Singer², ¹University Hospitals Parma Medical Center, Parma, OH, ²The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Janus kinase (JAK) inhibitors are immunosuppressive medications that target the JAK-STAT signaling pathway. Tofacitinib (Xeljanz) was the first JAK inhibitor approved for the treatment…
Abstract Number: 1103 • ACR Convergence 2025
Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Kayla Chubbs¹, Carrie Ye², Shahin Jamal³, Marie Hudson⁴, Janet Pope⁵, Tom Appleton⁶, Sabrina Hoa⁷, Alexandra Saltman⁸, Megan Himmel⁸, Nancy Maltez⁹, Faiza Khokhar¹⁰, Alexandra Ladouceur¹¹, Ines Colmegna¹², May Choi¹³, Manar Elsayed² and Janet Roberts¹, ¹Dalhousie University, Halifax, NS, Canada, ²University of Alberta, Edmonton, AB, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵University of Western Ontario, London, ON, Canada, ⁶Western University, London, ON, Canada, ⁷University of Montreal, Brossard, QC, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹Department of Medicine, Division of Rheumatology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ¹⁰Hamilton Ontario, Hamilton, ON, Canada, ¹¹University of Montreal, Montreal, QC, Canada, ¹²The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹³University of Calgary, Calgary, AB, Canada
Background/Purpose: The use of immune checkpoint inhibitors (ICI) continues to increase with an expanding number of indications across varying cancer types and stages. ICIs can…
Abstract Number: 1024 • ACR Convergence 2025
Mortality In Progressive Pulmonary Fibrosis Associated to Autoimmune Diseases: NEREA Registry
Marta Ruiz-Valdepeñas Almansa¹, CLARA DE MIGUEL², DALIFER FREITES³, Cristina Vadillo Font⁴, Maria asuncion Nieto⁴, Olga Sanchez Pernaute⁵, fredeswinda Romero-Bueno⁶, Mª Jesus Rodriguez-Nieto⁷, Rosalia Laporta⁸, Hilda Godoy Tundidor⁹, Jesús Loarce¹⁰, Juan A Rigual¹¹ and lydia Abasolo Alcazar¹², ¹HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, ²HOSPITAL CLINICO SAN CARLOS, Madrid, Madrid, Spain, ³Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁴Hospital Clínico S Carlos, Madrid, Spain, ⁵Clinica Universidad de Navarra, Madrid, Madrid, Spain, ⁶University Hospital Fundación Jiménez Díaz"", Madrid, Spain, ⁷Fundacion Jimenez Diaz (IIS-HUFJD), Madrid, Spain, ⁸Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ⁹Hospital Universitario puerta de hierro, Madrid, Spain, ¹⁰HOSPITAL RAMÓN Y CAJAL, MADRID, Madrid, Spain, ¹¹Hospital Ramón y Cajal, Madrid, Spain, ¹²IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Autoimmune interstitial lung disease (ILD) may arise in various autoimmune rheumatic diseases (ARD). Some patients develop ILD with systemic symptoms and autoantibodies without fulfilling…
Abstract Number: 1104 • ACR Convergence 2025
Immune Checkpoint Inhibitors and Cardiovascular Risk in Patients with Rheumatoid Arthritis and Cancer
Kevin Sheng-Kai Ma¹, Rachael Stovall², Jeffrey Sparks³, You Wu², Richard Cheng⁴, Gregory Challener⁵, Hans von Eckstaedt², Bhavik Bansal⁶, Petros Grivas⁷, Steven Chen⁸, Jean Liew⁹ and Namrata Singh⁷, ¹Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Philadelphia, PA, ²University of Washington, Seattle, WA, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Washington, Seaattle, WA, ⁵MGH, Boston, MA, ⁶UT Southwestern Medical Centre, Dallas, TX, ⁷University of Washington, BELLEVUE, WA, ⁸Massachusetts General Hospital, Boston, ⁹Boston University, Boston, MA
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) face a higher lifetime burden of cardiovascular disease (CVD) vs the general population with approximately 1.5-2-fold increase in…
Abstract Number: 1120 • ACR Convergence 2025
Synergistic Effects of IL-17F and IL-17A on Neutrophil Chemotaxis: Increased Risk of Candidiasis with Dual Blockade of IL-17A and IL17-F
Siba Raychaudhuri¹, Disha Chakraborty², Christine Abria² and Smriti K Raychaudhuri³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²Sacramento VA Medical Center, Mather, CA, ³Sacramento VA Medical Center, Davis, CA
Background/Purpose: IL-17 is primarily secreted by Th17 cells. The IL-17 family has 6 related cytokines (IL-17A to IL17F); IL-17A and IL-17F, being key proinflammatory mediators.…
Abstract Number: 1126 • ACR Convergence 2025
Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis
Coralie Tremblay¹, Nathalie Carrier², Hugues Allard-Chamard³, Javier Marrugo⁴, Sophie Roux⁴, Gilles Boire⁵ and Ariel Masetto⁴, ¹Université de Sherbrooke, Division of Rheumatology, Department of Medicine and Health Sciences, Sherbrooke, Canada, and Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS), Sherbrooke, Canada, Saint-Augustin-de-Desmaures, QC, Canada, ²Centre integré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie-CHUS), Sherbrooke, Canada, ³Université de Sherbrooke, Sherbrooke, Canada, ⁴Université de Sherbrooke, Division of Rheumatology, Department of Medicine and Health Sciences, Sherbrooke, Canada, and Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie – CHUS), Sherbrooke, Canada, Sherbrooke, Canada, ⁵Retired, Sherbrooke, QC, Canada
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a common cause of arthropathy over the age of 60. It can also manifest as a chronic polyarticular…
Abstract Number: 1113 • ACR Convergence 2025
Immune checkpoint inhibitor–associated myocarditis: Incidence, risk factors, and clinical outcomes in a global real-world cohort
Qi Wang¹, Zhiting Tang² and Lei Deng³, ¹Metrohealth System/Case Western Reserve University, Cleveland, OH, ²Unity Hospital, Rochester, NY, ³Fred Hutchinson Cancer Center, Seattle, WA
Background/Purpose: Immune checkpoint inhibitor (ICI)-associated myocarditis is a rare but life-threatening immune-related adverse event (irAE), with a mortality rate of 30–50%. Most available evidence comes…
Abstract Number: 1026 • ACR Convergence 2025
Seasonal Variation in Public Interest in Gout Made More Crystal-Clear: A Longitudinal Infodemiology Study Using Google Trends.
Naomi Schlesinger¹ and Ioannis Androulakis², ¹Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT, ²Rutgers University, Piscataway, NJ
Background/Purpose: Understanding public interest in gout, as reflected by online behavior, can offer valuable insights into its perception and management. Infodemiology, which examines the distribution…
Abstract Number: 1063 • ACR Convergence 2025
Gender, Racial, and Geographic Trends in Mortality from Interstitial Lung Diseases Among Patients With Rheumatoid Arthritis in the U.S. Population, 1999–2020
Farheen Malik¹, Jawad Ahmed², Mandar Shah¹, Ritika Uttam³ and Muhammad Fahimuddin¹, ¹Jacobi Medical Center, Bronx, NY, NY, ²Northwest Health Porter, Valpraiso, IN, ³Jacobi Medical Center, Bronx, NY
Background/Purpose: Rheumatoid arthritis (RA) is a common autoimmune disease affecting up to 1.0% of the US population. RA is most commonly associated with synovial inflammation…
Abstract Number: 1130 • ACR Convergence 2025
Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia
Kiara Tan¹, Jiaqi Wang¹, Saiajay Chigurupati², Gregory Challener³, Natalie McCormick¹, Sharan Rai⁴, Florence Porterfield⁵, Chika Anekwe¹, Dong Wook Kim⁶, Fatima Stanford⁷, Caroline Apovian⁸, Hyon K. Choi⁹ and Chio Yokose¹⁰, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Division of Endocrinology, Massachusetts General Hospital, Boston, ⁶Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Boston, ⁷Neuroendocrine Unit, Pediatric Endocrinology, Massachusetts General Hospital, Boston, ⁸Brigham and Women's Hospital, Boston, ⁹MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ¹⁰Massachusetts General Hospital, Waltham, MA
Background/Purpose: Obesity affects >50% of individuals with gout and is the most important modifiable risk factor for gout. Thus, novel anti-obesity medications (AOM, e.g., semaglutide…
Abstract Number: 1139 • ACR Convergence 2025
Synovial Counts, Cultures, and Crystals: An Analysis of 9,000 Aspirations
Sabahat Usmani¹, Gunjan Rana², Shivum Patel¹, Patrick Kennedy¹ and Michael Putman³, ¹Medical College of Wisconsin, Milwaukee, ²Saint Vincent Hospital, Worcester, MA, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Synovial fluid analysis is an essential diagnostic tool for evaluating crystalline and infectious arthritis. Traditionally, a leukocyte count threshold of >50,000 cells/µL has been…
Abstract Number: 1127 • ACR Convergence 2025
The Pathogenetic Role of Calcium Pyrophosphate and Basic Calcium Phosphate Crystals in Osteoarthritis: Associations with Synovial Fluid Cytokines and Clinical Indices
Francesca Oliviero¹, Chiara Baggio², Amelia Damasco², Federico Zorzi³, Mariagrazia Lorenzin², Giacomo Cozzi² and Roberta Ramonda⁴, ¹Rheumatology Unit, Department od Medicine - DIMED, University of Padova, Padova, Veneto, Italy, ²Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Veneto, Italy, ³Center for Analysis and Certification Services (CEASC), University of Padova, Padova, Veneto, Italy, ⁴Rheumatology Unit-DIMED-University of Padova ITALY, Padova, Padua, Italy
Background/Purpose: Calcium pyrophosphate (CPP) and basic calcium phosphate (BCP) crystals are frequent features of synovial fluid (SF) in patients with osteoarthritis (OA). Although these crystals…
Abstract Number: 1083 • ACR Convergence 2025
How Do Social Determinants of Health Differ Across Age and Disability Groups Among Adult Medicare Advantage Enrollees with Systemic Lupus Erythematosus?
Alexjandro Daviano¹, Vijay R. Nadipelli², Yihua Xu¹, Karen Worley², Shireen Haq¹, Josephine Ohioma³, Jeffrey J. Ellis², Brandon T. Suehs¹ and S. Sam Lim⁴, ¹Humana Healthcare Research, Inc., Louisville, KY, ²GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, ³GSK, US Medical Affairs, Philadelphia, PA, ⁴Emory University School of Medicine, Atlanta, GA
Background/Purpose: Management of patients with SLE should consider social determinants of health (SDoH) and their impact on access, treatment, and patient outcomes; however, such a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].